Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)

Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The company has developed and is commercializing its Cardiac Recovery System platform a comprehensive and advanced system that integrates monitoring therapeutic treatment digital health and patient support services into a single unified solution. The cornerstone of the Cardiac Recovery System platform is the ASSURE WCD a next generation wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the US. The ASSURE WCD automatically monitors elevated risk patients and if needed delivers a defibrillation shock to return the patient's heart to normal rhythm. The device was purpose-built to enhance patient comfort and compliance directly addressing key barriers to adoption associated with the only other commercially available wearable cardioverter defibrillator.

Kestra Medical Technologies, Ltd. generates revenue primarily through a lease business model for its ASSURE WCD as part of the Cardiac Recovery System platform. Patients are prescribed the device by healthcare providers for specific durations typically three months or longer. The company fits patients with the ASSURE WCD in hospital clinic or home settings and directly bills various third-party payors including Medicare Medicaid and private insurers for the lease period. In addition to the core ASSURE WCD the platform includes fully integrated digital solutions such as the ASSURE patient application for real-time mobile updates and compliance tracking the Kestra CareStation remote patient data platform for provider analytics and alert management Heart Alert Services and ASSURE Assist services for emergency response coordination and the recently FDA-cleared ASSURE wearable ECG for extended monitoring post-WCD therapy. These components work together to create a seamless patient and provider experience throughout the cardiac care continuum.

Kestra Medical Technologies, Ltd. operates in the wearable cardioverter defibrillator market which has historically been served by a single incumbent commercial product the LifeVest WCD marketed by ZOLL. Since the first WCD received approval in 2001 global WCD revenues have grown to $1.3 billion in 2023 with approximately 85% generated in the US market. Despite clinical proof of safety and efficacy WCD therapy remains significantly underutilized reaching only 14% of the eligible US patient population in 2023. The company attributes this low penetration to limitations of the incumbent device including high false alarm rates (reported at 46% for users) poor wearability due to a unisex-only garment and limited patient-provider connectivity. The ASSURE WCD differentiates itself through multiple clinical and functional advantages: it delivers a 170 joule shock for improved efficacy in high-defibrillation-threshold patients features gender-specific garment designs developed with an athletic and sportswear designer incorporates cushioned electrodes for enhanced electrocardiogram signal quality utilizes four-channel electrocardiography with Adaptive Patient Intelligence technology to reduce false alarms to approximately 6% of users and provides a minimum of 25 shocks for safety during cardiac events such as ventricular tachycardia storms. These innovations position the company to address the substantial unmet need in a market where the addressable opportunity is estimated at approximately $10 billion annually in the US and $14 billion in international markets based on patient epidemiology and reimbursement rate analyses.

Kestra Medical Technologies, Ltd. serves patients indicated for wearable cardioverter defibrillator therapy which includes individuals at risk for sudden cardiac arrest who are not candidates for or refuse implantable cardioverter defibrillator treatment. Based on the company's analysis of epidemiological data there are approximately 800,000 cardiac patients annually in the US who have experienced myocardial infarction or heart failure with low left ventricular ejection fraction making them eligible for WCD therapy. An additional approximately 50,000 patients each year qualify due to documented ventricular tachycardia ventricular fibrillation inherited cardiac conditions or temporary explantation of implantable cardioverter defibrillators. The company's customer base consists of healthcare providers who prescribe the ASSURE WCD including general cardiologists, interventional cardiologists, cardiac electrophysiologists, cardiothoracic surgeons, hospitalists, nurse practitioners, and physician assistants. As of April 30 2025 more than 20,000 patients have worn the ASSURE WCD since its full commercial launch in August 2022 demonstrating early adoption and the company has established commercial relationships with healthcare facilities across the United States ranging from major academic medical centers to community hospitals. The company maintains a direct sales force of approximately 80 representatives supported by over 300 contracted patient specialists who assist with device fitting and training nationwide.